<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">docru</journal-id><journal-title-group><journal-title xml:lang="ru">Доктор.Ру</journal-title><trans-title-group xml:lang="en"><trans-title>Title</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-2378</issn><issn pub-type="epub">2713-2994</issn><publisher><publisher-name>ООО "ГК "РУСМЕДИКАЛ"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31550/1727-2378-2023-22-2-39-44</article-id><article-id custom-type="elpub" pub-id-type="custom">docru-228</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Диагностическая эффективность контраст-усиленного ультразвукового исследования у пациентов с хроническими вирусными гепатитами</article-title><trans-title-group xml:lang="en"><trans-title>Diagnostic Efficacy of Contrast-Enhanced Ultrasound in Patients with Chronic Viral Hepatitis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8037-9660</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тиханкова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tikhankova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тиханкова Анна Витальевна — к. м. н., младший научный сотрудник Проблемной научно-исследовательской лаборатории «Диагностические исследования и малоинвазивные технологии» ФГБОУ ВО СГМУ Минздрава России.</p><p>214019, Смоленск, ул. Крупской, д. 28</p></bio><bio xml:lang="en"><p>28 Krupskoy Str., Smolensk, 214019</p></bio><email xlink:type="simple">annatikh67@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4047-7252</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Борсуков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borsukov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Борсуков Алексей Васильевич — д. м. н., профессор, директор Проблемной научно-исследовательской лаборатории «Диагностические исследования и малоинвазивные технологии» ФГБОУ ВО СГМУ Минздрава России.</p><p>214019, Смоленск, ул. Крупской, д. 28</p></bio><bio xml:lang="en"><p>28 Krupskoy Str., Smolensk, 214019</p></bio><email xlink:type="simple">bor55@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Smolensk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2025</year></pub-date><volume>22</volume><issue>2</issue><issue-title>ТЕРАПИЯ</issue-title><fpage>39</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тиханкова А.В., Борсуков А.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Тиханкова А.В., Борсуков А.В.</copyright-holder><copyright-holder xml:lang="en">Tikhankova A.V., Borsukov A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://docru.elpub.ru/jour/article/view/228">https://docru.elpub.ru/jour/article/view/228</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: определить диагностическую эффективность КУУЗИ у пациентов с хроническими вирусными гепатитами В и С.</p></sec><sec><title>Дизайн</title><p>Дизайн: открытое рандомизированное сравнительное исследование.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В 2019–2021 гг. на базе ОГБУЗ «Клиническая больница № 1» г. Смоленска были обследованы 240 человек: пациенты с хроническими вирусными гепатитами, которым было проведено КУУЗИ; пациенты с хроническими вирусными гепатитами, которым не было проведено КУУЗИ для определения диагностической эффективности метода в оценке развития осложненного течения; пациенты без хронических вирусных гепатитов, которым было проведено КУУЗИ для определения стандартизированных параметров исследования. В качестве референтных методов служили биопсия печени и эластография сдвиговых волн.</p></sec><sec><title>Результаты</title><p>Результаты. Наибольшие изменения параметров контрастирования наблюдались у пациентов со стадией фиброза F4 по классификации METAVIR. Установлено, что наиболее высоким диагностическим потенциалом обладает оценка качественных параметров по предложенной стандартизированной программе, а среди количественных параметров — значения разницы количественных параметров в проксимальных и дистальных зонах (начало артериальной фазы, время достижения максимальной интенсивность накопления контрастного препарата, максимальная интенсивность накопления контрастного препарата, время полувыведения контрастного препарата).</p></sec><sec><title>Заключение</title><p>Заключение. Использование контрастного препарата увеличивает ценность ультразвукового метода в диагностическом алгоритме при хронических вирусных гепатитах.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim: to determine the diagnostic efficiency of contrast-enhanced ultrasound of the liver in patients with chronic viral hepatitis B and C.</p></sec><sec><title>Study Design</title><p>Study Design: open randomized study.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 240 people were examined on the basis of the Smolensk Clinical Hospital No. 1 from 2019 to 2021: patients with chronic viral hepatitis who have been examined by contrast-enhanced ultrasound; patients with chronic viral hepatitis who have not been examined by contrast-enhanced ultrasound to determine the diagnostic effectiveness of the method in assessing the complicated course development, patients without chronic viral hepatitis who have been examined by contrast-enhanced ultrasound to determine the standardized CEUS parameters. Liver biopsy and shear wave elastography were used as reference methods.</p></sec><sec><title>Results</title><p>Results. It was found that the greatest changes in contrast-enhanced ultrasound parameters were observed in patients with F4 fibrosis stage according to the METAVIR score. It was also found that the assessment of qualitative parameters according to the proposed standardized program has the highest diagnostic potential, and among the quantitative parameters — the difference of quantitative parameters in the proximal and distal zones (time of arrival, time to peak, peak intensity, half-time washout).</p></sec><sec><title>Conclusion</title><p>Conclusion. The use of a contrast agent increases the value of the ultrasound method in the diagnostic algorithm for patients with chronic viral hepatitis.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>контраст-усиленное ультразвуковое исследование</kwd><kwd>хронические вирусные гепатиты</kwd><kwd>контрастный препарат</kwd><kwd>артериальная фаза</kwd><kwd>портальная венозная фаза</kwd><kwd>поздняя венозная фаза</kwd><kwd>качественные параметры</kwd><kwd>количественные параметры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>contrast-enhanced ultrasound</kwd><kwd>chronic viral hepatitis</kwd><kwd>contrast agent</kwd><kwd>arterial phase</kwd><kwd>portal venous phase</kwd><kwd>late venous phase</kwd><kwd>qualitative parameters</kwd><kwd>quantitative parameters</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Сенча А.Н. Ультразвуковое исследование с применением контрастных препаратов. От простого к сложному. М.; 2021. 296 с.</mixed-citation><mixed-citation xml:lang="en">Sencha A.N. Ultrasound examination with the use of contrast agents. From simple to complex. Moscow; 2021. 296 p. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dietrich C.F., Christian P.N., Richard G.B. et al. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver — Update 2020: WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med. 2020;41(5):562–585.</mixed-citation><mixed-citation xml:lang="en">Dietrich C.F., Christian P.N., Richard G.B. et al. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver — Update 2020: WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med. 2020;41(5):562–585.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Weskott H.-P. Contrast-enhanced ultrasound. Bremen; 2014. 284 p.</mixed-citation><mixed-citation xml:lang="en">Weskott H.-P. Contrast-enhanced ultrasound. Bremen; 2014. 284 p.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Борсуков А.В. Контрастно-усиленное ультразвуковое исследование печени: эволюция оценок мировых экспертов с 2012 по 2020 гг. Онкологический журнал: лучевая диагностика, лучевая терапия. 2021;4(1):20–30. DOI: 10.37174/2587-7593-2021-4-1-20-30</mixed-citation><mixed-citation xml:lang="en">Borsukov A.V. Contrast-enhanced ultrasound of the liver: evolution of the world experts opinions from 2012 to 2020. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2021;4(1):20–30. (in Russian). DOI: 10.37174/2587-7593-2021-4-1-20-30</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Claudon M., Dietrich C.F., Choi B.I. et al. Guidelines and good clinical practice recommendations for contrast enchanced ultrasound (CEUS) in the liver — update 2012: a WFUMB — EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound in Medicine and Biology. 2013;9(2):187–210. DOI: 10.1016/j.ultrasmedbio.2012.09.002</mixed-citation><mixed-citation xml:lang="en">Claudon M., Dietrich C.F., Choi B.I. et al. Guidelines and good clinical practice recommendations for contrast enchanced ultrasound (CEUS) in the liver — update 2012: a WFUMB — EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound in Medicine and Biology. 2013;9(2):187–210. DOI: 10.1016/j.ultrasmedbio.2012.09.002</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Митьков В.В., Садоков В.М., Хитрова А.Н. и др. Неинвазивная допплерографическая диагностика цирроза печени на основе анализа времени поступления эхоконтрастного вещества в печеночные вены. Ультразвуковая и функциональная диагностика. 2001;(2):14–18.</mixed-citation><mixed-citation xml:lang="en">Mit'kov V.V., Sadokov V.M., Hitrova A.N. et al. Non-invasive dopplerographic diagnostics of liver cirrhosis on the basis of the transit-time analysis for the ultrasound contrast agent entering into the hepatic veins. Ultrasound &amp; Functional Diagnostics. 2001;(2):14–18. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ridolfi F., Abbattista T., Marini F. et al. Contrast-enchanced ultrasound to evaluate the severity of chronic hepatitis C. Digestive and Live Disease. 2007;39:929–935.</mixed-citation><mixed-citation xml:lang="en">Ridolfi F., Abbattista T., Marini F. et al. Contrast-enchanced ultrasound to evaluate the severity of chronic hepatitis C. Digestive and Live Disease. 2007;39:929–935.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Шифф Ю.Р., Соррел М.Ф., Мэддрей У.С. Вирусные гепатиты и холестатические заболевания. М.; 2010. 408 с.</mixed-citation><mixed-citation xml:lang="en">Shiff Yu.R., Sorrel M.F., Maddrey U.S. Viral hepatitis and cholestatic diseases. Moscow; 2010. 408 p. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cosgrove D. Contrast-enchanced ultrasound of the liver. London; 2010:64.</mixed-citation><mixed-citation xml:lang="en">Cosgrove D. Contrast-enchanced ultrasound of the liver. London; 2010:64.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Liu G.J., Lu M.D. Diagnosis of liver cirrhosis with contrast-enhanced ultrasound. World J. Radiol. 2010;2(1):32–36. DOI: 10.4329/wjr.v2.i1.32</mixed-citation><mixed-citation xml:lang="en">Liu G.J., Lu M.D. Diagnosis of liver cirrhosis with contrast-enhanced ultrasound. World J. Radiol. 2010;2(1):32–36. DOI: 10.4329/wjr.v2.i1.32</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017;67(2):370–398. DOI: 10.1016/j.jhep.2017.03.021</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017;67(2):370–398. DOI: 10.1016/j.jhep.2017.03.021</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for Study of Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73(5):1170–1218. DOI: 10.1016/j.jhep.2020.08.018</mixed-citation><mixed-citation xml:lang="en">European Association for Study of Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73(5):1170–1218. DOI: 10.1016/j.jhep.2020.08.018</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67(4):1560–1599. DOI: 10.1002/hep.29800</mixed-citation><mixed-citation xml:lang="en">Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67(4):1560–1599. DOI: 10.1002/hep.29800</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis. 2018;67(10):1477–1492. DOI: 10.1093/cid/ciy585</mixed-citation><mixed-citation xml:lang="en">Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis. 2018;67(10):1477–1492. DOI: 10.1093/cid/ciy585</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Борсуков А.В., Буеверов А.О., Тиханкова А.В. Возможности контраст-усиленного ультразвукового исследования в диагностике цирроза печени. Медицинский алфавит. 2019;3(29):26–30.</mixed-citation><mixed-citation xml:lang="en">Borsukov A.V., Bueverov A.O., Tihankova A.V. Capabilities of contrast-enhanced ultrasound in the diagnosis of liver cirrhosis. Medicinskij alfavit. 2019. 2019;3(29):26–30. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Борсуков А.В., Тиханкова А.В. Способ прогнозирования клинического течения диффузных заболеваний печени. Патент на изобретение RU 2713944 от 11.02.2020.</mixed-citation><mixed-citation xml:lang="en">Borsukov A.V., Tihankova A.V. A method for predicting the clinical course of diffuse liver diseases. Invention Patent RU 2713944, 11.02.2020. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Petrie A., Sabin K. Medical statistics at a glance. Hoboken; 2020. 4th ed.</mixed-citation><mixed-citation xml:lang="en">Petrie A., Sabin K. Medical statistics at a glance. Hoboken; 2020. 4th ed.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
